John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 14,100 shares at $174.14 ($2.5M) on 2021-02-01, disclosed to the SEC on 2021-02-03.
Open-market sale of $2.5M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $174.14 | 400 | $70K | 2.8% |
| 2 | $175.38 | 3,094 | $543K | 21.9% |
| 3 | $175.38 | 3,094 | $543K | 21.9% |
| 4 | $176.14 | 2,304 | $406K | 16.4% |
| 5 | $176.14 | 2,304 | $406K | 16.4% |
| 6 | $177.23 | 1,202 |
| $213K |
| 8.6% |
| 7 | $177.23 | 1,202 | $213K | 8.6% |
| 8 | $178.16 | 300 | $53K | 2.2% |
| 9 | $178.98 | 200 | $36K | 1.4% |
| Total | $176.02 avg | 14,100 | $2.5M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |